FIELD: medicine.
SUBSTANCE: invention refers to medicine and pharmacology and concerns using of nanophospholipid composition of rifampicine together with protionamide or its nanophospholipid form for treatment of tuberculosis.
EFFECT: invention provides reducing of collateral toxic damage.
1cl, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
ANTITUBERCULOUS COMPOSITION AND METHOD FOR PREPARING IT | 2011 |
|
RU2472512C1 |
COMBINED ANTITUBERCULOSIS PREPARATION (RIZOBUTOL) | 2002 |
|
RU2195937C1 |
ANTI-TUBERCULOSIS MEDICATION BASED ON 4-THIOUREIDOIMINOMETHYLPYRIDINIUM PERCHLORATE, METHOD OF ITS OBTAINING AND METHOD OF TREATMENT | 2010 |
|
RU2423977C1 |
METHOD FOR ESTIMATING ANTIMYCOBACTERIAL ACTION OF ANTI-TUBERCULOSIS DRUGS USING BIOLOGICAL MATERIAL OF PATIENTS WITH PULMONARY TUBERCULOSIS | 2017 |
|
RU2677972C1 |
PHARMACEUTICAL ANTI-TUBERCULOSIS COMBINED COMPOSITION | 2011 |
|
RU2478389C2 |
COMBINED ANTITUBERCULOUS COMPOSITION | 2009 |
|
RU2413517C1 |
COFORMULATED ANTITUBERCULOUS DRUG | 2009 |
|
RU2430724C2 |
METHOD OF TREATING TUBERCULOSIS WITH MULTIPLE DRUG RESISTANCE | 2013 |
|
RU2554753C2 |
COMBINED ANTITUBERCULOUS COMPOSITION | 2010 |
|
RU2468802C2 |
STRAIN MYCOBACTERIUM TUBERCULOSIS 326/18/47 B-9673 FOR EVALUATION OF THE EFFECTIVENESS OF ANTI-TB DRUGS AND DISINFECTANTS | 2022 |
|
RU2785409C1 |
Authors
Dates
2016-08-27—Published
2014-10-15—Filed